

# Global Cancer Vaccine Market & Clinical Trial Insight

<https://marketpublishers.com/r/G073617F1BDEN.html>

Date: September 2015

Pages: 750

Price: US\$ 4,000.00 (Single User License)

ID: G073617F1BDEN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

The concept of vaccines dates back to 1881, when Edward Jenner developed the first vaccine to treat small pox. Since then many technological advancements have been made, in modern times, vaccines have been developed as a new therapeutic for prevention and eradication of cancer. Currently, ranges of therapeutics are available in market to effectually combat cancer, but they suffer from several glitches like low effectiveness and high unspecificity. Researchers came up with the idea of cancer vaccines to alleviate patients suffering from cancer.

Conventionally, vaccines were used for the prevention of contagious diseases, they work by boosting the immune response against the pathogens. Analogously, cancer vaccines work by activating the immune system to attack on cancer cells. Researchers developed cancer vaccines to alleviate patients suffering from cancer. With the technological advances, cancer vaccines have been developed as a new therapeutic for cancer prevention and eradication. Currently, ranges of therapeutics are available in market to effectually combat cancer, but they suffer from several glitches like low effectiveness and high unspecificity.

The cancer vaccines have revolutionized the present views and methodologies of cancer treatment. As a result of which plenty of biotech companies are exploring the field of cancer vaccines. This has caused the development of numerous cancer vaccines for numerous types of cancer. Pharmaceutical companies are using these vaccines for clinical trials; few of them are already available to the patients across the world. The US and EU were the first markets to approve the cancer vaccines for therapeutic usage. As compared to rest of the world, commercialization and development in these regions have already made a significant progress.

The attractiveness for cancer vaccines has increased in past few years due to their characteristic properties like less side effects, low toxicity and high specificity. Besides, innovations related to novel delivery methods have also made them a lucrative option. Unlike traditional methods, they can be used for targeting the sub-group of cancers without effecting normal cells. Another factor in their favor is their high efficacy levels as compared to the presently available cancer therapeutics.

The market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category.

The cancer vaccines have to go through a long journey before enjoying the status of blockbuster drug. Presently, they have achieved a lot of success in both therapeutic and preventive field. However, inclination of market and researchers seems to be more towards the preventive category of cancer vaccines. For therapeutic side, it should be noted that novel methods for cancer eradication has been made. The future of cancer vaccines looks optimistic and plenty of cancer vaccines will hit the shelf in coming years.

“Global Cancer Vaccine Market & Clinical Trial Insight” Report Highlights:

Global Cancer Market Overview

Emergence of Personalized Cancer Vaccines

Platforms for Cancer Vaccines Delivery

Mechanism of Cancer Vaccines

Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country

Global Cancer Vaccine Clinical Pipeline: 298 Vaccines

Marketed Cancer Vaccines: 15 Vaccines

## Regulatory Framework for Cancer Vaccines Development & Marketing

## Contents

### **1. INTRODUCTION TO CANCER VAACINES**

### **2. MECHANISM OF CANCER VACCINES**

- 2.1 Idiotypic Cancer Vaccine Mechanism
- 2.2 Cellular Cancer Vaccines Mechanism
- 2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
- 2.4 Peptide Cancer Vaccine Mechanism
- 2.5 Tumor Host Interaction Cancer Vaccine Mechanism

### **3. ADJUVANTS THERAPY FOR CANCER VACCINES**

### **4. GLOBAL CANCER VACCINES MARKET OVERVIEW**

- 4.1 Current Market Scenario
- 4.2 Global Cancer Vaccine Drug Pipeline by Indication

### **5. EMERGENCE OF PERSONALIZED CANCER VACCINES**

### **6. PUBLIC HPV CANCER VACCINATION PROGRAM**

### **7. GLOBAL CANCER VACCINES MARKET DYNAMICS**

- 7.1 Favorable Market Parameters
  - 7.1.1 Pottential Demand for Cancer Vaccines
  - 7.1.2 Public Cancer Vaccination Program
  - 7.1.3 Advancements in Development Technology
  - 7.1.4 Personalized Cancer Vaccines
  - 7.1.5 Myriad of Demographs for Cancer Vaccine Development
- 7.2 Commercialization Challenges

### **8. GLOBAL CANCER VACCINE MARKET FUTURE OUTLOOK**

### **9. BLADDER CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE**

## 9.1 Phase-II

### **10. BLOOD CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE**

#### 10.1 Research till Preregistration

### **11. BRAIN CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE**

#### 11.1 Preclinical Till Phase-III

### **12. BREAST CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE**

#### 12.1 Preclinical till Phase-III

### **13. CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE**

#### 13.1 Research till Phase-II

### **14. CERVICAL CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE**

#### 14.1 Phase-II

### **15. COLORECTAL CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE**

#### 15.1 Preclinical till Preregistration

### **16. HEAD AND NECK CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE**

#### 16.1 Preclinical till Phase-I/II

### **17. LIVER CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE**

17.1 Phase-I till Phase-II

## **18. LUNG CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE**

18.1 Preclinical till Phase-III

## **19. OESOPHAGEAL CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE**

19.1 Phase-III

## **20. OVARIAN CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE**

20.1 Preclinical till Phase-III

## **21. PANCREATIC CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE**

21.1 Reseach till Phase-III

## **22. PROSTATE CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE**

22.1 Preclinical till Phase-III

## **23. RENAL CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE**

23.1 Phase-I till Phase-III

## **24. SARCOMA VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE**

24.1 Phase-II

## **25. SKIN CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE**

25.1 Preclinical till Phase-III

## **26. SOLID TUMOURS VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE**

26.1 Preclinical till Phase-II

## **27. MULTIPLE CANCER VACCINE CLINICAL PIPELINE INSIGHT BY COMPANY & PHASE**

27.1 Preclinical till Phase-III

## **28. MARKETING CANCER VACCINE CLINICAL INSIGHT BY COMPANY & INDICATION**

28.1 Bladder Cancer

28.1.1 BCG Bladder Cancer Vaccine (Immucyst® & TheraCys®)

28.1.2 Bladder Cancer Vaccine (PACIS®)

28.1.3 Bladder Cancer Vaccine - Organon Teknika

28.2 Cervical Cancer

28.2.1 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix®)

28.3 Lung Cancer

28.3.1 BV NSCLC

28.3.2 Cadi 05 (Immuvac® & Mycidac-C™)

28.3.3 Racotumomab (Vaxira®)

28.4 Pancreatic Cancer

28.4.1 Tertomotide (LucaVax)

28.5 Prostate Cancer

28.5.1 Sipuleucel-T (Provenge®)

28.6 Renal Cancer

28.6.1 Renal Cancer Vaccine (Reniale®)

28.6.2 Vitespen (Oncophage®)

28.7 Skin Cancer

28.7.1 Melanoma Vaccine (MVax®)

28.7.2 Melanoma Vaccine (Melacine®)

28.8 Multiple Cancer

28.8.1 Human Papillomavirus Vaccine 9-Valent (V503) (GARDASIL®9)

28.8.2 Human Papillomavirus Vaccine Quadrivalent (Gardasil® & Silgard®)

## **29. DISCONTINUED & SUSPENDED CANCER VACCINE DRUG CLINICAL PIPELINE INSIGHT**

29.1 No Development Reported

29.2 Discontinued

29.3 Suspended

## **30. FDA REGULATORY FRAMEWORK FOR CANCER VACCINES DEVELOPMENT & MARKETING**

30.1 Considerations for both Early and Late Phase Clinical Trials

30.1.1 Patient Population

30.1.2 Monitoring the Immune Response

30.1.3 Biomarkers as Evidence Of Efficacy

30.1.4 Adjuvants Used To Stimulate Immune Response

30.1.5 Multi-Antigen Vaccines

30.1.6 Disease Progression/Recurrence Immediately Or Shortly After The Initial Administration Of Cancer Vaccines

30.1.7 Concomitant and Subsequent Therapies

30.2 Considerations for Early Phase Clinical Trials

30.2.1 Starting Dose and Dosing Schedule

30.2.2 Booster and Maintenance Therapy

30.2.3 Dose Escalation

30.2.4 Single-Arm versus Randomized Phase 2 Trials In Early Development

30.3 Considerations for Late Phase Clinical Trials

30.3.1 Safety Profile from Early Phase Clinical Trials

30.3.2 Endpoints

30.3.3 Statistical Issues

30.3.4 Control Issues

30.3.5 Delayed Vaccine Effect

30.3.6 Autologous Vaccine Trials

30.3.7 Accelerated Approval Regulations

## **31. COMPETITIVE LANDSCAPE: BUSINESS OVERVIEW & PRODUCT PIPELINE**

31.1 Advaxis

31.2 AVAX Technologies

31.3 Celldex Therapeutics

31.4 Dendreon Corporation



- 31.5 Galena Biopharma
- 31.6 GlaxoSmithKline
- 31.7 ImmunoCellular Therapeutics
- 31.8 ImmunoGen
- 31.9 Inovio Pharmaceuticals
- 31.10 KAEL-GemVax
- 31.11 Liponova
- 31.12 MedImmune
- 31.13 Merck
- 31.14 NeoStem Oncology
- 31.15 NewLink Genetics
- 31.16 Northwest Biotherapeutics
- 31.17 Novartis
- 31.18 Peregrine Pharmaceuticals
- 31.19 Recombio
- 31.20 Roche
- 31.21 Sanofi
- 31.22 Seattle Genetics
- 31.23 Valeant Pharmaceuticals

## List Of Figures

### LIST OF FIGURES

- Figure 1-1: Categorization & Function of Cancer Vaccines
- Figure 2-1: Classification of Different Types of Cancer vaccines
- Figure 4-1: Global Cancer Vaccines Market (US\$ Billion), 2014-2020
- Figure 4-2: Global Cancer Vaccines Market by Region (%), 2014 & 2020
- Figure 4-3: Examples of Commercially Available Cancer Vaccines
- Figure 4-4: Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-5: Cancer Vaccine Drug Pipeline by Phase (Number), 2015
- Figure 4-6: Bladder Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-7: Bladder Cancer Vaccine Drug Pipeline by Phase (Number), 2015
- Figure 4-8: Blood Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-9: Blood Cancer Vaccine Drug Pipeline by Phase (Number), 2015
- Figure 4-10: Brain Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-11: Brain Cancer Vaccine Drug Pipeline by Phase (Number), 2015
- Figure 4-12: Breast Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-13: Breast Cancer Vaccine Drug Pipeline by Phase (Number), 2015
- Figure 4-14: Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-15: Cancer Vaccine Drug Pipeline by Phase (Number), 2015
- Figure 4-16: Cervical Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-17: Cervical Cancer Vaccine Drug Pipeline by Phase (Number), 2015
- Figure 4-18: Colorecta Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-19: Colorecta Cancer Vaccine Drug Pipeline by Phase (Number), 2015
- Figure 4-20: Head & Neck Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-21: Head & Neck Cancer Vaccine Drug Pipeline by Phase (Number), 2015
- Figure 4-22: Liver Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-23: Liver Cancer Vaccine Drug Pipeline by Phase (Number), 2015
- Figure 4-24: Lung Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-25: Lung Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-26: Ovarian Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-27: Ovarian Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-28: Pancreatic Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-29: Pancreatic Cancer Vaccine Drug Pipeline by Phase (Number), 2015
- Figure 4-30: Prostate Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-31: Prostate Cancer Vaccine Drug Pipeline by Phase (Number), 2015
- Figure 4-32: Renal Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-33: Renal Cancer Vaccine Drug Pipeline by Phase (Number), 2015

- Figure 4-34: Skin Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-35: Skin Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-36: Solid Tumour Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-37: Solid Tumour Vaccine Drug Pipeline by Phase (Number), 2015
- Figure 4-38: Multiple Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-39: Multiple Cancer Vaccine Drug Pipeline by Phase (Number), 2015
- Figure 4-40: No Development Reported Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-41: No Development Reported Cancer Vaccine Drug Pipeline by Phase (Number), 2015
- Figure 4-42: Discontinued Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-43: Discontinued Cancer Vaccine Drug Pipeline by Phase (Number), 2015
- Figure 4-44: Suspended Cancer Vaccine Drug Pipeline by Phase (%), 2015
- Figure 4-45: Suspended Cancer Vaccine Drug Pipeline by Phase (Number), 2015
- Figure 5-1: Overview of Personalized Cancer Vaccines Development
- Figure 5-2: Methodology for the Development of Personalized Cancer Vaccine
- Figure 5-3: Schematic Representation of Development of Skin Implant for Cancer Vaccine
- Figure 6-1: Prophylactic Cancer Vaccines Available for Different Serotypes of HPV
- Figure 7-1: Factors Responsible for High Demand of Cancer Vaccines
- Figure 31-1: Advaxis Clinical Pipeline
- Figure 31-2: Celldex Therapeutics Clinical Pipeline
- Figure 31-3: Galena Biopharma Clinical Pipeline
- Figure 31-4: ImmunoCellular Therapeutics Clinical Pipeline
- Figure 31-5: ImmunoGen Clinical Pipeline
- Figure 31-6: Inovio Pharmaceuticals Clinical Pipeline
- Figure 31-7: KAEL-Genvax Clinical Pipeline
- Figure 31-8: NewLink Genetics Corporation Clinical Pipeline
- Figure 31-9: Northwest Biotherapeutics Clinical Pipeline
- Figure 31-10: Peregrine Pharmaceuticals Clinical Pipeline
- Figure 31-11: Seattle Genetics Clinical Pipeline

## List Of Tables

### LIST OF TABLES

Table 5-1: Different Types of Biomarkers For Personalized Cancer Vaccine Development

### COMPANIES

Advaxis  
AVAX Technologies  
Celldex Therapeutics  
Dendreon Corporation  
Galena Biopharma  
GlaxoSmithKline  
ImmunoCellular Therapeutics  
ImmunoGen  
Inovio Pharmaceuticals  
KAEL-GemVax  
Liponova  
MedImmune  
Merck  
NeoStem Oncology  
NewLink Genetics  
Northwest Biotherapeutics  
Novartis  
Peregrine Pharmaceuticals  
Recombio  
Roche  
Sanofi  
Seattle Genetics  
Valeant Pharmaceuticals

## I would like to order

Product name: Global Cancer Vaccine Market & Clinical Trial Insight

Product link: <https://marketpublishers.com/r/G073617F1BDEN.html>

Price: US\$ 4,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G073617F1BDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970